The Board of Directors of Human Variome Project International Limited is responsible for the governance, policy development, strategic planning and financial sustainability of the Human Variome Project. The Board consists of six directors and an independent Chair, each serving a three year term, with two seats being vacated each year. The membership of the Board of Directors is open to prominent members of the scientific community, major funders of the Human Variome Project and appropriate interested persons. Three members of the Board are appointed by the Scientific Advisory Committee from amongst their members, and three are elected by the members of the Human Variome Project International Limited (as distinct from the members of the Human Variome Project Consortium). The Chair is appointed by the Board of Directors.

The current Board of Directors is serving in an interim capacity until the full Board is elected.

The Board of Directors is responsible for:

• setting and reviewing medium and long term goals
• appointing the CEO and evaluating the CEO’s performance
• monitoring the performance of the International Coordinating Office
• approving budgets
• approving large funding or other major financial decisions
• ensuring major risks are identified and managed
• challenging the assumptions of the leadership team
• ensuring there is accurate financial reporting and the organisation complies with all aspects of the law
• ensuring appropriate development and remuneration of the leadership (CEO and Scientific Director)
• communicating with current and prospective strategic partners and key stakeholders

Interim Board Members

• Mr David Abraham (Chair)
• Mr Chris Arnold
• Professor Richard Cotton
• Professor Xitao Li